{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:39:51Z","timestamp":1790959191564,"version":"4.1.0"},"reference-count":60,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>T cells engineered with chimeric antigen receptors (CARs) have revolutionized the field of cell therapy and changed the paradigm of treatment for many patients with relapsed or refractory B-cell malignancies. Despite this progress, there are limitations to CAR-T cell therapy in both the autologous and allogeneic settings, including practical, logistical, and toxicity issues. Given these concerns, there is a rapidly growing interest in natural killer cells as alternative vehicles for CAR engineering, given their unique biological features and their established safety profile in the allogeneic setting. Other immune effector cells, such as invariant natural killer T cells, \u03b3\u03b4 T cells, and macrophages, are attracting interest as well and eventually may be added to the repertoire of engineered cell therapies against cancer. The pace of these developments will undoubtedly benefit from multiple innovative technologies, such as the CRISPR-Cas gene editing system, which offers great potential to enhance the natural ability of immune effector cells to eliminate refractory cancers.<\/jats:p>","DOI":"10.1182\/hematology.2020002547","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T23:47:55Z","timestamp":1607125675000},"page":"570-578","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":48,"title":["Next-generation cell therapies: the emerging role of CAR-NK cells"],"prefix":"10.1182","volume":"2020","author":[{"given":"Rafet","family":"Basar","sequence":"first","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Daher","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Rezvani","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6382","key":"2020121621273964200_B1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"5","key":"2020121621273964200_B2","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.ymthe.2017.03.034","article-title":"Chimeric antigen receptors: a cell and gene therapy perspective","volume":"25","author":"Rivi\u00e8re","year":"2017","journal-title":"Mol Ther"},{"issue":"8","key":"2020121621273964200_B3","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"17","key":"2020121621273964200_B4","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res"},{"issue":"2","key":"2020121621273964200_B5","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2020121621273964200_B6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/imr.12774","article-title":"Updates on CAR T-cell therapy in B-cell malignancies","volume":"290","author":"Jacoby","year":"2019","journal-title":"Immunol Rev"},{"issue":"5","key":"2020121621273964200_B7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"2020121621273964200_B8","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2020121621273964200_B9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"2020121621273964200_B10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcyt.2018.11.009","article-title":"Manufacturing chimeric antigen receptor T cells: issues and challenges","volume":"21","author":"Roddie","year":"2019","journal-title":"Cytotherapy"},{"issue":"5","key":"2020121621273964200_B11","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/trf.14003","article-title":"Autologous lymphapheresis for the production of chimeric antigen receptor T cells","volume":"57","author":"Allen","year":"2017","journal-title":"Transfusion"},{"key":"2020121621273964200_B12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"issue":"16","key":"2020121621273964200_B13","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"5 suppl","key":"2020121621273964200_B14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1200\/JCO.2018.36.5_suppl.122","article-title":"Correlation of patient characteristics and biomarkers with clinical outcomes of JCAR017 in R\/R aggressive B-NHL (TRANSCEND NHL 001 study)","volume":"36","author":"Siddiqi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020121621273964200_B15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy: assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"2020121621273964200_B16","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"issue":"10","key":"2020121621273964200_B17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/cells7100155","article-title":"Allogeneic CAR-T cells: more than ease of access?","volume":"7","author":"Graham","year":"2018","journal-title":"Cells"},{"issue":"6","key":"2020121621273964200_B18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/MOH.0000000000000181","article-title":"Challenges and opportunities of allogeneic donor-derived CAR T cells","volume":"22","author":"Yang","year":"2015","journal-title":"Curr Opin Hematol"},{"issue":"7643","key":"2020121621273964200_B19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"issue":"9","key":"2020121621273964200_B20","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.leukres.2013.05.016","article-title":"Follicular lymphoma with leukemic phase at diagnosis: a series of seven cases and review of the literature","volume":"37","author":"Beltran","year":"2013","journal-title":"Leuk Res"},{"issue":"1","key":"2020121621273964200_B21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark Res"},{"issue":"3","key":"2020121621273964200_B22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.blre.2005.10.001","article-title":"Human natural killer cell development and biology","volume":"20","author":"Farag","year":"2006","journal-title":"Blood Rev"},{"key":"2020121621273964200_B23","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"2020121621273964200_B24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: you can teach innate cells new tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2020121621273964200_B25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.coi.2018.03.013","article-title":"Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering","volume":"51","author":"Daher","year":"2018","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"2020121621273964200_B26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"issue":"5562","key":"2020121621273964200_B27","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"2020121621273964200_B28","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3389\/fimmu.2015.00266","article-title":"Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications","volume":"6","author":"Carlsten","year":"2015","journal-title":"Front Immunol"},{"issue":"3","key":"2020121621273964200_B29","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/cancers12030706","article-title":"You have got a fast CAR: chimeric antigen receptor NK cells in cancer therapy","volume":"12","author":"Pfefferle","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2020121621273964200_B30","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2217\/imt.11.131","article-title":"Use of allogeneic NK cells for cancer immunotherapy","volume":"3","author":"Geller","year":"2011","journal-title":"Immunotherapy"},{"issue":"23","key":"2020121621273964200_B31","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1182\/bloodadvances.2019000835","article-title":"A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation","volume":"3","author":"Li","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"2020121621273964200_B32","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5966\/sctm.2012-0084","article-title":"Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy","volume":"2","author":"Knorr","year":"2013","journal-title":"Stem Cells Transl Med"},{"issue":"4","key":"2020121621273964200_B33","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: an \u201coff-the-shelf therapeutic\u201d for adoptive natural killer cell\u2013based cancer immunotherapy","volume":"65","author":"Suck","year":"2016","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"2020121621273964200_B34","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41577-018-0034-2","article-title":"Tissue-specific functions of invariant natural killer T cells","volume":"18","author":"Crosby","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2020121621273964200_B35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cellimm.2015.04.008","article-title":"Human gamma delta T cells: evolution and ligand recognition","volume":"296","author":"Adams","year":"2015","journal-title":"Cell Immunol"},{"issue":"2","key":"2020121621273964200_B36","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","article-title":"Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation","volume":"26","author":"Capsomidis","year":"2018","journal-title":"Mol Ther"},{"issue":"12","key":"2020121621273964200_B37","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1182\/blood-2011-02-336321","article-title":"Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity","volume":"118","author":"Pievani","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2020121621273964200_B38","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2020121621273964200_B39","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1089\/hum.2017.207","article-title":"Preclinical efficacy and safety of CD19CAR cytokine-induced killer cells transfected with Sleeping Beauty transposon for the treatment of acute lymphoblastic leukemia","volume":"29","author":"Magnani","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"8","key":"2020121621273964200_B40","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/ijc.30217","article-title":"Chimeric antigen receptor\u2013engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival","volume":"139","author":"Oelsner","year":"2016","journal-title":"Int J Cancer"},{"issue":"5","key":"2020121621273964200_B41","doi-asserted-by":"crossref","first-page":"e1423167","DOI":"10.1080\/2162402X.2017.1423167","article-title":"CD44v6 as innovative sarcoma target for CAR-redirected CIK cells","volume":"7","author":"Leuci","year":"2018","journal-title":"OncoImmunology"},{"issue":"39","key":"2020121621273964200_B42","doi-asserted-by":"crossref","first-page":"66137","DOI":"10.18632\/oncotarget.19821","article-title":"Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children","volume":"8","author":"Merker","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2020121621273964200_B43","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1038\/s41598-017-04756-9","article-title":"5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells","volume":"7","author":"Guo","year":"2017","journal-title":"Sci Rep"},{"issue":"8","key":"2020121621273964200_B44","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"11","key":"2020121621273964200_B45","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.3390\/ijms20112839","article-title":"CAR-based strategies beyond T lymphocytes: integrative opportunities for cancer adoptive immunotherapy","volume":"20","author":"Rotolo","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2020121621273964200_B46","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/mt.2016.10","article-title":"Genome-editing technologies for gene and cell therapy","volume":"24","author":"Maeder","year":"2016","journal-title":"Mol Ther"},{"issue":"6405","key":"2020121621273964200_B47","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1126\/science.aat5011","article-title":"CRISPR-Cas guides the future of genetic engineering","volume":"361","author":"Knott","year":"2018","journal-title":"Science"},{"issue":"1","key":"2020121621273964200_B48","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/s41467-018-04252-2","article-title":"The CRISPR tool kit for genome editing and beyond","volume":"9","author":"Adli","year":"2018","journal-title":"Nat Commun"},{"issue":"R1","key":"2020121621273964200_B49","doi-asserted-by":"crossref","first-page":"R40","DOI":"10.1093\/hmg\/ddu125","article-title":"CRISPR\/Cas9 for genome editing: progress, implications and challenges","volume":"23","author":"Zhang","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"6096","key":"2020121621273964200_B50","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"issue":"9","key":"2020121621273964200_B51","doi-asserted-by":"crossref","first-page":"e0198714","DOI":"10.1371\/journal.pone.0198714","article-title":"Highly multiplexed genome engineering using CRISPR\/Cas9 gRNA arrays","volume":"13","author":"Kurata","year":"2018","journal-title":"PLoS One"},{"key":"2020121621273964200_B52","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1038\/mtna.2015.37","article-title":"Off-target effects in CRISPR\/Cas9-mediated genome engineering","volume":"4","author":"Zhang","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"2020121621273964200_B53","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"6","key":"2020121621273964200_B54","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nmeth.4278","article-title":"CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets [published correction appears in Nat Methods, 2018;15:394]","volume":"14","author":"Tsai","year":"2017","journal-title":"Nat Methods"},{"issue":"1","key":"2020121621273964200_B55","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1472-6750-11-80","article-title":"RNase H-dependent PCR (rhPCR): improved specificity and single nucleotide polymorphism detection using blocked cleavable primers","volume":"11","author":"Dobosy","year":"2011","journal-title":"BMC Biotechnol"},{"issue":"8","key":"2020121621273964200_B56","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","article-title":"A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells","volume":"24","author":"Vakulskas","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"2020121621273964200_B57","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"issue":"6481","key":"2020121621273964200_B58","doi-asserted-by":"crossref","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"2020121621273964200_B59","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells [published online ahead of print 9 September 2020]","author":"Daher","journal-title":"Blood"},{"issue":"7","key":"2020121621273964200_B60","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.bbmt.2019.03.004","article-title":"Clearance of hematologic malignancies by allogeneic cytokine-induced killer cell or donor lymphocyte infusions","volume":"25","author":"Merker","year":"2019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/570\/1795161\/hem2020002547c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/570\/1795161\/hem2020002547c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T13:21:59Z","timestamp":1608297719000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/570\/474363\/Nextgeneration-cell-therapies-the-emerging-role-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020002547","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}